期刊
THORACIC SURGERY CLINICS
卷 30, 期 2, 页码 127-136出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.thorsurg.2020.01.008
关键词
Non-small cell lung cancer; EGFR mutations; EGRF-TKIs; Erlotinib; Afatinib; Osimertinib; Resistance mechanisms
Up to 20% of lung adenocarcinomas in the United States and Europe and 50% in Asia have activating mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). The identification and subsequent targeting of mutations with EGFR-tyrosine kinase inhibitors (TKIs) led to significant advances in treatment of EGFR-mutant lung cancer. Newer-generation EGFR-TKIs resulted in improvement in outcomes, with less toxic side effects and better tolerability. Resistance to EGFR-TKIs remains a significant barrier, and better understanding of resistance mechanisms is needed. Efforts are ongoing to incorporate targeted therapy into treatment of patients with earlier-stage disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据